Company: RVRC
Filing Date: 2025-10-03
Form Type: S-1/A
Source: 0001213900-25-096094
Chunk: 93

Company: Revium Rx.
Filing Date: 2025-10-03
Form: S-1/A
Chunk 93
---
     | EP-CH   |     | Oct. 11, 2016 |     | Liposomal Mupirocin |     |      3142642 |     | August 29, 2018   |     |         3142642 |     | April 8, 2035 |
| Granted |     | EP-GB   |     | Oct. 11, 2016 |     | Liposomal Mupirocin |     |      3142642 |     | August 29, 2018   |     |         3142642 |     | April 8, 2035 |
| Granted |     | CN      |     | Oct. 10, 2016 |     | Liposomal Mupirocin |     |    106659795 |     | June 2, 2023      |     |       106659795 |     | April 8, 2035 |
| Granted |     | JP      |     | Oct. 6, 2016  |     | Liposomal Mupirocin |     |  2017-513938 |     | March 13, 2020    |     |         6676035 |     | April 8, 2035 |
| Granted |     | IN      |     | Oct. 19, 2016 |     | Liposomal Mupirocin |     | 201627035738 |     | November 23, 2020 |     |          351893 |     | April 8, 2035 |

Market Opportunity and Estimated Commercial Potential for Systemic Liposomal Nano-Mupirocin

Clinical Background and Unmet Need

Gonorrhea, caused by Neisseria gonorrhoeae, is
one of the most common sexually transmitted infections globally. The U.S. Centers for Disease Control and Prevention (CDC) recommends
Ceftriaxone as the first-line treatment [2]. Resistance is a growing threat. However, strains resistant to Ceftriaxone are emerging, posing
a serious public health threat [3].

We are working to develop Liposomal Mupirocin
as a systemic treatment alternative for Ceftriaxone-resistant infections, with the potential to offer improved tissue penetration, higher
drug concentration at the site of the infection and sustained drug exposure.

<div align='center'>58</div>

Pricing Benchmark and Market Assumptions

Our pricing assumptions are based on